Editas Medicine Stock Short Ratio
| EDIT Stock | USD 5.35 0.11 2.01% |
Editas Medicine fundamentals help investors to digest information that contributes to Editas Medicine's financial success or failures. It also enables traders to predict the movement of Editas Stock. The fundamental analysis module provides a way to measure Editas Medicine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Editas Medicine stock.
Editas | Short Ratio |
Editas Medicine Company Short Ratio Analysis
Editas Medicine's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Editas Medicine Short Ratio | 6.85 X |
Most of Editas Medicine's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Editas Medicine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Editas Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Editas Medicine is extremely important. It helps to project a fair market value of Editas Stock properly, considering its historical fundamentals such as Short Ratio. Since Editas Medicine's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Editas Medicine's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Editas Medicine's interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Editas Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Editas Medicine has a Short Ratio of 6.85 times. This is 75.64% higher than that of the Biotechnology sector and 7.56% lower than that of the Health Care industry. The short ratio for all United States stocks is 71.25% lower than that of the firm.
Editas Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Editas Medicine's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Editas Medicine could also be used in its relative valuation, which is a method of valuing Editas Medicine by comparing valuation metrics of similar companies.Editas Medicine is currently under evaluation in short ratio category among related companies.
Editas Medicine Current Valuation Drivers
We derive many important indicators used in calculating different scores of Editas Medicine from analyzing Editas Medicine's financial statements. These drivers represent accounts that assess Editas Medicine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Editas Medicine's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.5B | 4.1B | 1.8B | 609.1M | 769.5M | 1.0B | |
| Enterprise Value | 1.3B | 4.0B | 1.6B | 511.5M | 682.4M | 921.9M |
Editas Medicine Institutional Holders
Institutional Holdings refers to the ownership stake in Editas Medicine that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Editas Medicine's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Editas Medicine's value.| Shares | Marshall Wace Asset Management Ltd | 2023-12-31 | 1.1 M | Goldman Sachs Group Inc | 2023-12-31 | 1.1 M | Jpmorgan Chase & Co | 2023-12-31 | 1.1 M | Credit Suisse First Boston (csfb) | 2023-12-31 | 896.5 K | Woodline Partners Lp | 2023-12-31 | 895.4 K | Northern Trust Corp | 2023-12-31 | 870 K | Charles Schwab Investment Management Inc | 2023-12-31 | 684 K | D. E. Shaw & Co Lp | 2023-09-30 | 668.7 K | Nuveen Asset Management, Llc | 2023-12-31 | 645.8 K | Vanguard Group Inc | 2023-12-31 | 8.5 M | Blackrock Inc | 2023-12-31 | 7.8 M |
Editas Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (1.96) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 160.13 M | ||||
| Shares Outstanding | 82.23 M | ||||
| Shares Owned By Insiders | 0.30 % | ||||
| Shares Owned By Institutions | 80.14 % | ||||
| Number Of Shares Shorted | 16.36 M | ||||
| Price To Earning | (7.02) X | ||||
| Price To Book | 1.46 X | ||||
| Price To Sales | 6.50 X | ||||
| Revenue | 78.12 M | ||||
| Gross Profit | (155.25 M) | ||||
| EBITDA | (163.12 M) | ||||
| Net Income | (153.22 M) | ||||
| Cash And Equivalents | 452.56 M | ||||
| Cash Per Share | 6.59 X | ||||
| Total Debt | 36.54 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 12.67 X | ||||
| Book Value Per Share | 4.27 X | ||||
| Cash Flow From Operations | (132.18 M) | ||||
| Short Ratio | 6.85 X | ||||
| Earnings Per Share | (2.02) X | ||||
| Target Price | 15.64 | ||||
| Number Of Employees | 265 | ||||
| Beta | 2.02 | ||||
| Market Capitalization | 451.17 M | ||||
| Total Asset | 499.15 M | ||||
| Retained Earnings | (1.23 B) | ||||
| Working Capital | 277.61 M | ||||
| Current Asset | 144.99 M | ||||
| Current Liabilities | 6.92 M | ||||
| Net Asset | 499.15 M |
About Editas Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Editas Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Editas Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Editas Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Editas Medicine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Editas Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Editas Medicine will appreciate offsetting losses from the drop in the long position's value.Moving against Editas Stock
| 0.78 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.69 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.56 | ELYM | Eliem Therapeutics | PairCorr |
| 0.48 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Editas Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Editas Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Editas Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Editas Medicine to buy it.
The correlation of Editas Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Editas Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Editas Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Editas Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Editas Medicine Piotroski F Score and Editas Medicine Altman Z Score analysis. For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Editas Stock analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stocks Directory Find actively traded stocks across global markets |
Is Editas Medicine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share 1.028 | Quarterly Revenue Growth 8.187 | Return On Assets (0.21) | Return On Equity (0.43) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.